Back to News
Market Impact: 0.2
China Medical System: Singapore's HSA Clears Lumirix, First Topical Rx Drug For Vitiligo Treatment
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
China Medical System Holdings said its subsidiary, Rxilient Medical, received Singapore Health Sciences Authority approval on Tuesday, November 3, for Lumirix (ruxolitinib phosphate cream). The report provides no indication, sales outlook, or other details on the approval's commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- After the midterms, a bigger clash over data centers could be coming
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- After the midterms, Big Tech’s AI data center problem is only getting bigger